By partnering and collaborating with various organizations, we are able to strengthen our drug development operations. We are seeking collaborators to maximize the full potential of our lead candidate and licensing opportunities to complement our current platform. Please send business development inquiries via our Contact Us page.
In February 2021, we announced a licensing and strategic partnership agreement for ibrexafungerp with Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, that covers the Greater China region. We received a $10 million upfront payment and are eligible to receive development and commercial milestone payments of up to $112 million, plus low double-digit royalties on net sales.
More information can be found here.
Ibrexafungerp (formerly SCY-078) was initially discovered at our research facilities and developed as part of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. We are currently developing this product as a novel oral and intravenous (IV) drug for the treatment of multiple serious and often life-threatening fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and invasive fungal infections.